The TBAg/PHA Ratio in T-SPOT.TB Assay Has High Prospective Value in the Diagnosis of Active Tuberculosis: A Multicenter Study in China.

liu yidian

shanghai pulmonary hospital <https://orcid.org/0000-0003-2546-4189>

Yao Lan

shanghai pulmonary hospital

Wang Feng

Tongji hospital

Sun Ziyong

Tongji hospital

Tan Yaoju

Guangzhou Chest Hospital

wei sha (✉ shfksw@126.com)

Tongji University School of Medicine <https://orcid.org/0000-0002-2099-8205>

Research

Keywords: TBAg/PHA ratio, T-SPOT, Active tuberculosis, Non-tuberculosis, diagnosis

Posted Date: December 29th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-135748/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

The positive rate of pathogenic examination about tuberculosis is low. It is still difficult to achieve early diagnosis for some TB patients. The value of Interferon-gamma release assays (IGRA) in the diagnosis of active tuberculosis remains controversial. The purpose of this multicenter prospective study was to verify and validate the role of TBAg/PHA ratio (TB-specific antigen to phytohaemagglutinin) of T-SPOT.TB assay in diagnosing ATB.

Methods

We prospectively enrolled 2390 suspected pulmonary tuberculosis patients with positive T-SPOT assay results from three tertiary hospitals.

Results

A total of 1549 ATB(active tuberculosis) patients (including 1091 confirmed and 458 probable ATB) and 724 non-tuberculosis (non-TB) patients with positive T-SPOT results were included. The results of this study showed that ESAT-6 and CFP-10 in the T-SPOT.TB assay were significantly higher in the ATB group compared with the non-TB group, while PHA was lower in the ATB group. Results of ESAT-6 , CFP-10 and PHA show a certain diagnostic performance, but moderate sensitivity and specificity. The TBAg/PHA ratio, a further calculation of ESAT-6 , CFP-10 and PHA in T-SPOT.TB assay showed improved performance in the diagnosis of active Tuberculosis. If using the threshold value of 0.2004, the specificity and sensitivity of TBAg/PHA ratio in distinguishing ATB from non-TB were 92.3% and 74.4%, PPV was 95.4, PLR was 9.6.

Conclusion

By recalculating the results of T-SPOT.TB Assay , the TBAg/PHA ratio shows high prospect value in the diagnosis of active tuberculosis in high prediction areas.

Introduction

Tuberculosis (TB) is still one of the main causes of mortality worldwide. It is estimated that one-third of the world's population is infected with *Mycobacterium tuberculosis* (Mtb)[1]. Globally in 2018, an estimated 10.0 million people fell ill with TB[2]. Early diagnosis of pulmonary TB is crucial for preventing the spread of Mtb infection. However, it is still difficult to achieve early diagnosis and timely treatment for some TB patients. Diagnostic assessment of suspected tuberculosis can also be lengthy, costly, and burdensome for patients and health-care systems[3].

Conventional TB diagnosis continues to rely on smear microscopy, mycobacterium culture and chest radiography. These tests have known limitations[4-6]. The polymerase chain reaction (PCR)-based

GeneXpert MTB/RIF sputum assay improves the speed and specificity of TB diagnosis, but still has limited sensitivity under low bacterial loads[7, 8]. Therefore, GeneXpert MTB/RIF assay requires clinical specimens from anatomical disease sites, often requiring resource-intensive invasive procedures[9].

T-cell interferon- γ release assays (IGRAs) are based on interferon- γ (IFN- γ) secretion by lymphocytes exposed to *M. tuberculosis*-specific antigens (TBAg). IGRAs has been proven useful in the detection of *Mtb* infection[10-12]. Because of the good performance, IGRAs was established for the immunodiagnosis of latent tuberculosis infection (LTBI) in many countries, and recommended by WHO [13]. Although the analysis showed that the sensitivity of IGRAs was not high enough to use as a rule out test for TB [14]. But a number of different studies on IGRAs in the diagnosis of active tuberculosis (ATB) have been published in recent years, suggesting that the role of IGRA in the diagnosis of ATB is still worth further evaluation[15, 16], some prospective studies are needed.

T-SPOT.TB (T-SPOT) assay, as one of two commercially available IGRAs, is widely used in clinical practice. The degree to which the magnitude of the T-SPOT.TB results were found to be determined largely by the host immune response[17], and speculated to be associated with mycobacterial antigen load (which reflects bacterial load)[18, 19]. Some studies report that T-SPOT has certain diagnostic value for active tuberculosis, and has higher diagnostic accuracy of active TB[14, 16], but the specificity and sensitivity have not yet reached practical application. We found that phytohemagglutinin (PHA) results in T-SPOT assay can reflect the immune status of the patient[20]. Our group has previously shown that calculation of the ratio of MTB-specific antigen (TBAg) to phytohaemagglutinin (PHA) (TBAg/ PHA ratio) in T-SPOT assay has the potential to distinguish certain types of ATB from LTBI[21, 22]. That was a retrospective and case-control study.

Therefore, we conducted a prospective study to validate the diagnostic value of TBAg/PHA ratio for active tuberculosis. Meanwhile, we also provide important up-to-date information for further using T-SPOT to distinguish active tuberculosis from LTBI.

Materials And Methods

Study design and participants

This study was conducted at three tertiary hospitals including Shanghai Pulmonary Hospital, Tongji Hospital and Guangzhou Chest Hospital in China. The hospitals are located in the east, center, and south of China. Between October 2016 and October 2017, patients who were suspected with pulmonary TB and had undergone the T-SPOT.TB test were enrolled at three hospitals. Patients with suspected pulmonary TB mean he/she have TB-related symptoms (fever, fatigue, chest pain, cough, night sweats, weight loss, productive sputum) and abnormal pulmonary radiographic evidence consistent with active pulmonary TB (lung infiltrations, fibronodular lesions and cavitory lesion). Candidates were excluded if they refuse to do T-SPOT.TB assay or age younger than 16 years. Participants were excluded from this study if they have a negative T-SPOT.TB result or indeterminate T-SPOT.TB result.

Clinical and laboratory procedures

Participants were investigated in routine practice under the direction of the infectious disease or respiratory medicine attending physician. Patient's data were collected of the demographics and medical history of the participant and subsequent investigations performed during routine diagnostic work-up. Bronchial washing fluid was collected from the lung segment that showed abnormal lesions on CT or chest X-ray. Sputum samples and other clinical specimens were collected for performing mycobacterium culture, GeneXpert MTB/RIF assay, AFS(Ziehl-Neelsen staining), pathological examination, general bacteriological culture, fungal culture, etc.

The patients with negative Mtb results will undergo further examination and necessary treatment based on the consideration of clinicians. In some patients, bronchoscopy biopsy or CT-guided biopsy were performed to assist the diagnosis if necessary. If other diseases were excluded, the clinician still considers active TB to be highly possibility, anti-TB treatment will be started after full communication and consent with the patient. Participants were followed up for 2 months or 6 months to collect data when necessary. If antituberculosis treatment was initiated, their response was recorded and followed up.

Peripheral blood T-SPOT assay was performed according to the manufacturer's instructions (Oxford Immunotec, Oxford, England) in three hospitals. T-SPOT.TB test was performed according to the manufacturers instructions. The results were double-checked if necessary, and corrected by manual counting. The laboratory technicians were blinded to the subject identifiers. Calculation of TBAG/PHA ratio: the ratios of (1) ESAT-6 sfc to PHA sfc, and (2) CFP-10 sfc to PHA sfc were calculated. The higher of these two values was defined as the TBAG/PHA ratio for one patient.

Diagnostic criteria

All participants have clinical and radiological features suggestive of tuberculosis, and the diagnose was categorised into the following groups: 1) ATB: including confirmed TB and probably TB;2)Confirmed ATB: Mycobacterium tuberculosis was confirmed by mycobacterium culture or Xpert MTB/RIF assay of clinical specimens;3)Probable ATB: the clinical and radiological findings were highly suggestive of TB, but both the results of mycobacterium culture and GeneXpert MTB/RIF assay were negative, and were appropriate response to anti-TB treatment after a follow-up of at least 2 months according to the decision of the clinician;4)non-tuberculosis (non-TB) : refers to patients with radiological abnormalities but GeneXpert MTB/RIF negative and mycobacterium culture negative, and patients had final diagnosis as other diseases (cancer, pneumonia, bronchiectasis etc) after clinical examination or necessary treatment, and were no clinical basis for active TB. Non-TB in this study were individual who had other diseases and also LTBI. The final diagnosis and diagnosis category were decided by the experts of respiratory and infectious diseases. Participants without a final diagnosis meant that the disease still could not be confirmed until the follow-up of 6 months, but active tuberculosis was excluded.

Statistical analysis

Statistical analysis was performed using the statistical software GraphPad Prism (version 5.01; GraphPad, La Jolla, CA, USA.) and SPSS (version 21.0; IBM Corp, Chicago, IL, USA). Differences between groups were analysed using the Mann-Whitney U-test. Receiver operating characteristic (ROC) analysis was performed to determine the best cut off value for TBAg/PHA ratio, ESAT-6 sfc, CFP-10 sfc, and PHA sfc in distinguishing ATB from non-TB. Area under the curve (AUC) and cutoff values with the highest sum of sensitivity and specificity were identified. Sensitivity, specificity, positive and negative predictive values (PPV, NPV), and positive and negative likelihood ratios (PLR, NLR) for each threshold value were calculated. The sensitivity and specificity were calculated, along with 95% confidence interval (CI), using the Wilson score method. Spearman's rank correlation test for non-parametric data was employed to analyze the relationship between two factors. Statistical significance was determined as $p < 0.05$.

Results

Study population and clinical characteristics

A total of 3729 subjects with suspected diagnosis of pulmonary TB were recruited from three tertiary hospitals. Finally, there were 2390 (64.09%) patients with positive T-SPOT results enrolled in the study. The patients ($n=10$) refused to receive diagnostic anti-TB treatment, and the patients ($n=11$) lost follow-up during anti-TB treatment. Among these patients, 1549 (64.8%) patients were finally diagnosed with ATB, including 1091 (70.4%) confirmed TB cases, and 458 (29.6%) probable ATB (Fig. 1). There were 724 (30.3%) patients were finally diagnosed with non-TB. Among the 724 non-TB cases, including 39.2% (284/724) bacterial pneumonia, 16.3% (118/724) bronchiectasis, 12.3% (89/724) lung cancer, 11.8% (86/724) nontuberculous mycobacteria infection, 7.3% (53/724) fungal infection, 4.6% (33/724) virus infection and 1.9% (14/724) parasitic infection; and 6.4% (47/724) other diseases. 96 (0.04%) patients without final diagnosis (Figure 1). The demographic and clinical characteristics of the participants are shown in Table 1.

No significant difference was found in sex, human immunodeficiency virus infection, hematologic malignancy, solid tumor, chronic renal failure, autoimmune disease receiving treatment, diabetes mellitus. The rate of history of TB in the ATB group was higher than that in the non-TB group. More liver cirrhosis in ATB group than non-TB group ($P=0.016$), and transplantation receiving treatment ($P=0.036$) (Table 1).

Diagnostic performance of the T-SPOT.TB assay and TBAg/PHA ratio for active TB

We observed a significant increase in the results of ESAT-6 in ATB group compared with non-TB ($P<0.0001$) (Fig 2A, Tab 2). The mean value of ESAT-6 were 90 ± 107.2 (mean $\pm$ SD) sfc in ATB group, and 16.9 ± 23.91 sfc in non-TB group. The mean value of CFP-10 were 150.1 ± 161.7 sfc in ATB group and 18.48 ± 27.59 sfc in non-TB group. There was also a significant increase in the results of CFP-10 in ATB group compared with non-TB ($P<0.0001$) (Fig 2A, Tab 2).

Compared the results of ESAT-6 in Confirmed ATB group(mean $\pm$ SD:92.67 $\pm$ 109.6 sfc) with non-TB group, and Probable ATB group(83.63 $\pm$ 101 sfc) with non-TB group, there were statistically significant differences(both $P < 0.001$). Compared the results of CFP-10 in Confirmed ATB group(mean $\pm$ SD:160 $\pm$ 166.8 sfc) with non-TB group, and Probable ATB group(126.4 $\pm$ 146.1 sfc) with non-TB group, there were statistically significant differences(both $P < 0.001$).

There was a significant decrease in the results of PHA in ATB group compared with non-TB($P < 0.0001$) (Fig 2A, Tab 2). The mean value of PHA was 286.3 $\pm$ 165.5 (mean $\pm$ SD) SFCs/ 2.5×10^5 in ATB group, and 387.1 $\pm$ 152.2 SFCs/ 2.5×10^5 in non-TB group. Compared the results of PHA in Confirmed ATB group(273.9 $\pm$ 163.3 SFCs/ 2.5×10^5) with non-TB group, and Probable ATB group(315.9 $\pm$ 167 SFCs/ 2.5×10^5) with non-TB group, there were statistically significant differences(both $P < 0.001$).

The AUC of the receiver operating characteristic (ROC) curve for ESAT-6 was 0.832 (95% CI 0.814–0.849) in distinguishing ATB from non-TB, CFP-10 was 0.839 (95% CI 0.823–0.855), and PHA was 0.671(95% CI 0.648–0.694) (Fig 2B, Tab 2). Meanwhile, we compared the confirmed ATB and Probable ATB vs non-TB, the results were similar (Fig 2A, Tab 2).

We calculated the TBAg/PHA ratio of every individual (the larger value of ESAT-6 sfc to PHA sfc or CFP-10 sfc to PHA sfc). We observed a significant increase in the results of TBAg/PHA ratio ($P < 0.0001$) in ATB group compared with non-TB group(Figure 2B). The median values and IQR of TBAg/PHA ratio were 0.5(0.192-1.10) and 0.052(0.029-0.097) in the ATB group and the non-TB group. The AUC of ROC curve for TBAg/PHA ratio was 0.911 (95% CI 0.899–0.922) in distinguishing ATB from non-TB(Figure 2B).

These data suggest that directly using PHA results has no enough value(AUC =0.671) in distinguishing the ATB and the non-TB. The AUC of ESAT-6 and CFP-10 were performed a certain value in distinguishing the two group, but the TBAg/PHA ratio showed outstanding performance. Therefore, we focus on a comprehensive analysis of the TBAg/PHA ratio.

The performance of different thresholds of Tbag/PHA ratio for ATB diagnosis

According to the statistical analysis of ROC curve, the TBAg/PHA ratio in distinguishing the ATB group and the non-TB group showed that the best threshold value was 0.1443. When the threshold value of 0.1443 was used, the sensitivity was 81.73% (95% CI 79.71% -83.63%) and the specificity was 86.6% (95% CI 83.9%- 89%), giving a PPV of 92.9 (95% CI 91.5-94.0%) and a PLR of 6.1 (95% CI 5.1-7.3) for ATB. This optimal threshold (0.1443) may show the best balance between sensitivity and specificity, but we generally need better specificity and sometimes need better sensitivity. Therefore, we calculated the performance of different thresholds, as shown in Table 3.

According to ROC analysis, if a specificity of more than 90% will be obtained, TBAg/PHA ratio threshold value of 0.1817 should be used to discriminate between ATB and non-TB. When TBAg/PHA ratio threshold value was 0.2004, the specificity was 92.27% (95% CI 90.07%- 94.1%) and the sensitivity was 74.37% (95% CI 72.12%- 76.53%) (Table 3). If sensitivity of more than 90% will be obtained, a threshold

value of 0.0783 should be used, the sensitivity was 90.06% (95% CI 88.46%- 91.5%) and the specificity was 67.82% (95% CI 64.28%- 71.21%). Compared TBAg/PHA ratio in the confirmed ATB group or probable ATB group vs non-TB group, the ROC analysis results were similar(Figure 2B, Table 3).

The TBAg/PHA ratio and diseases affecting host immune status

We analyzed the relationship between the results of T-SPOT.TB assay and diseases affecting host immune status. The underlying conditions listed in Table 1 were considered as immunosuppressive status, such as HIV infection, autoimmune disease receiving treatment, etc. The results of ESAT-6 and CFP-10 in immunocompromised patients were lower than others, while ESAT-6 and CFP-10 results in non-TB patients were even lower(Figure 3A). But the results of PHA were different, PHA value increased in non-TB patients (Figure 3A). The result of TBAg/PHA ratio showed that it was the highest among immunocompromised patients. ROC analysis showed that compared with ESAT-6 and CFP-10, the AUC of Tbag/PHA ratio in immunocompromised ATB and non-TB was closer, suggesting that Tbag/PHA ratio is less affected by the immune status of the host (Figure 3B).

The TBAg/PHA ratio and the types of ATB and patient's condition

Some types of tuberculosis or the patient's condition shows that their immune status was different from that of general ATB patients, T-SPOT assay's results can reflect it. We observed that ESAT-6 sfc, CFP-10 sfc, and TBAg/PHA ratio were increased in miliary tuberculosis patients and drug-resistant ATB patients compared with all ATB patients (Figure 4A). But it was not observed in patients with cavitary pulmonary tuberculosis(cavity ATB) (Figure 4A). Furthermore, we observed that the TBAg/PHA ratio was positively correlated with erythrocyte sedimentation rate(ESR), C-reactive protein, and peripheral blood adenosine deaminase in ATB patients, while it was negatively correlated with the percentage of lymphocytes (Figure 4B). However, we did not observe a significant correlation between TBAg results with these indicators (Figure 4).

Discussion

The positive rate of pathogenic examination about tuberculosis is low, which makes it difficult for many tuberculosis patients to early diagnose. Meanwhile, there are few other early identification methods. Interferon-gamma release assays (IGRA) for specific immunological diagnosis of Mycobacterium tuberculosis infection have become available recently. But the value of IGRA in the diagnosis of active tuberculosis remains controversial. Several studies have demonstrated that IGRAs may be useful as supplemental tools in the diagnosis of active TB[23, 24].T-SPOT.TB assay is one of the two commercial IGRA assays, recent studies have reported that T-SPOT.TB has a certain diagnostic value for active pulmonary tuberculosis by increasing the threshold[25].

The results of this study showed that ESAT-6, CFP-10 and PHA in the T-SPOT.TB assay are helpful to distinguish ATB and non-TB(both $P<0.0001$) (Table 2). But the overall specificity of three indicators is moderate, the sensitivity is slightly poor.

In our previous studies, we have proposed a new method based on the calculation of the ratio of TBAg to PHA in the T-SPOT analysis [21, 26]. Through the retrospective study[21] (162 active TB patients and 97 LTBI), we concluded that the TBAg/PHA ratio(the higher value of ESAT-6/PHA or CFP-10/PHA ratios) in active TB patients were significantly higher than in individuals with LTBI. Therefore, we consider that the value of Tbag/PHA ratio may be helpful in the diagnosis of active tuberculosis. Therefore, the diagnostic utility of TBAg/PHA ratio was validated through this multicenter prospective study.

ROC analysis shows that ESAT-6, CFP-10, and PHA all have good AUC (all above 85%), but the AUC of the TBAg/PHA ratio can reach more than 90%. ROC analysis showed that using the best threshold 0.1413, the sensitivity was 81.73% (95% CI 79.71%-83.63%) and the specificity was 86.6% (95% CI 83.9%-89%). When using the threshold value of 0.1817, the specificity was 90.06% (95% CI 87.64%- 92.14%), with a good PPV and a PLR for ATB, which can reached a good clinical application value. When the TBAg/PHA ratio threshold value 0.2004 was used, the specificity can be further increased, the specificity was 92.3% (95% CI 90.1%- 94.1%). Threshold value 0.200 is a relatively simple and accurate value, which is convenient for calculation and used with very good specificity and acceptable sensitivity(Figure 2B).

As a detection of the body's immune response, the results of the T-SPOT.TB assay will be affected by the body's immune state(Table 1). But the TBAg/PHA ratio were not affected by the underlying conditions. Our previously study reported that even in the immunocompromised patients, the TBAg/PHA ratio have some significance for the diagnosis of TB disease [22], the results of this study are consistent with it.

However, our study also has some shortcomings. There were 1339 (35.9%) patients with negative T-SPOT results were excluded from this study. Some proportion of them may eventually be diagnosed with ATB. It has been reported that IGRA may be affected by NTM. In this study, 86 cases of NTM were identified through mycobacterium culture, of which 21cases (24.4%) were T-SPOT positive. No further analysis was made due to the small number of cases.

Conclusions

This prospective, multi-center clinical study reveals that the TBAg/PHA ratio in T-SPOT.TB Assay shows high prospective value in the diagnosis of Active Tuberculosis in T-SPOT positive patients. Especially when the TBAg/PHA ratio threshold is 0.2004, good specificity and PLR can be obtained. The TBAg/PHA ratio are less affected by diseases affecting host immune status. By calculating the TBAg/PHA ratio, this method might break through the limitation of using T-SPOT assay in in high-TB prediction areas and may help early diagnosis of ATB.

Abbreviations

IGRAs: Interferon-gamma release assays; Mtb: Mycobacterium tuberculosis; ATB: active tuberculosis; PHA: phytohaemagglutinin; ESAT-6:early secreting antigenic target-6;CFP-10:culture Filtrate Protein-10; LTBI: latent tuberculosis infection; WHO: World Health Organization; NTM: non-tuberculous mycobacteria

Declarations

Acknowledgements

We would like to thank all the authors, co-authors and their various teams of researchers who were involved in the prospective study.

Authors' contributions

SW and TYJ designed and coordinated the study. LYD ,YL ,WF and SZY were involved in data interpretation,analysis, revision, critique and preparation. All authors read and approved the final manuscript.

Funding

The study was supported by the National “13th Five-Year Plan”for the Prevention and Treatment of Infectious Diseases (2018ZX10722302) and the National Mega Project on Major Infectious Disease Prevention (2017ZX10103005-007) and by the National Natural Science Foundation of China (81401639). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

This study was approved by the ethical committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (TJ-IRB20190421).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Department of tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China. ² Shanghai Clinical Research Center for infectious disease(tuberculosis),Shanghai 200433, China. ³ Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ⁴ Department of Clinical Laboratory, Guangzhou Chest Hospital, Guangzhou, China.

References

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999 1999-08-18;282(7):677-86.
2. World Health Organization. Global tuberculosis report 2019. Geneva:World Health Organization,2019..
3. Whitworth HS, Aranday-Cortes E, Lalvani A. Biomarkers of tuberculosis: a research roadmap. BIOMARK MED 2013 2013-06-01;7(3):349-62.
4. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. EXPERT REV MOL DIAGN 2006 2006-05-01;6(3):423-32.
5. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000 2000-04-01;161(4 Pt 1):1376-95.
6. Monkongdee P, McCarthy KD, Cain KP, et al. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am J Respir Crit Care Med 2009 2009-11-01;180(9):903-8.
7. Evans CA. GeneXpert—a game-changer for tuberculosis control? PLOS MED 2011 2011-07-01;8(7):e1001064.
8. Ioannidis P, Papaventsis D, Karabela S, et al. Cepheid GeneXpert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with substantial clinical indications of tuberculosis and smear-negative microscopy results. J CLIN MICROBIOL 2011 2011-08-01;49(8):3068-70.
9. Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. LANCET INFECT DIS 2018 2018-01-01;18(1):76-84.
10. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. ANN INTERN MED 2007 2007-03-06;146(5):340-54.
11. Pai M, Riley LW, Colford JJ. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. LANCET INFECT DIS 2004 2004-12-01;4(12):761-76.
12. Sollai S, Galli L, de Martino M, Chiappini E. Systematic review and meta-analysis on the utility of Interferon-gamma release assays for the diagnosis of Mycobacterium tuberculosis infection in children: a 2013 update. BMC INFECT DIS 2014 2014-01-20;14 Suppl 1:S6.

13. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018.
14. Sester M, Sotgiu G, Lange C, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. *EUR RESPIR J* 2011 2011-01-01;37(1):100-11.
15. Janssens JP, Roux-Lombard P, Perneger T, Metzger M, Vivien R, Rochat T. Quantitative scoring of an interferon-gamma assay for differentiating active from latent tuberculosis. *EUR RESPIR J* 2007 2007-10-01;30(4):722-8.
16. Whitworth HS, Badhan A, Boakye AA, et al. Clinical utility of existing and second-generation interferon-gamma release assays for diagnostic evaluation of tuberculosis: an observational cohort study. *LANCET INFECT DIS* 2019 2019-02-01;19(2):193-202.
17. Pathan AA, Wilkinson KA, Klenerman P, et al. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. *J IMMUNOL* 2001 2001-11-01;167(9):5217-25.
18. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. *CHEST* 2010 2010-04-01;137(4):952-68.
19. Nicol MP, Pienaar D, Wood K, et al. Enzyme-linked immunospot assay responses to early secretory antigenic target 6, culture filtrate protein 10, and purified protein derivative among children with tuberculosis: implications for diagnosis and monitoring of therapy. *CLIN INFECT DIS* 2005 2005-05-01;40(9):1301-8.
20. Wang F, Yu J, Zhou Y, et al. The Use of TB-Specific Antigen/Phytohemagglutinin Ratio for Diagnosis and Treatment Monitoring of Extrapulmonary Tuberculosis. *FRONT IMMUNOL* 2018 2018-01-20;9:1047.
21. Wang F, Hou HY, Wu SJ, et al. Using the TBAg/PHA ratio in the T-SPOT((R)).TB assay to distinguish TB disease from LTBI in an endemic area. *Int J Tuberc Lung Dis* 2016 2016-04-01;20(4):487-93.
22. Bosco MJ, Hou H, Mao L, et al. The performance of the TBAg/PHA ratio in the diagnosis of active TB disease in immunocompromised patients. *INT J INFECT DIS* 2017 2017-06-01;59:55-60.
23. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. *MMWR Recomm Rep* 2010 2010-06-25;59(RR-5):1-25.
24. Xia H, Wang X, Li F, et al. Diagnostic values of the QuantiFERON-TB Gold In-tube assay carried out in China for diagnosing pulmonary tuberculosis. *PLOS ONE* 2015 2015-01-20;10(4):e121021.
25. Yang Q, Zhang C, Ruan Q, et al. Higher T-SPOT.TB threshold may aid in diagnosing active tuberculosis?: A real-world clinical practice in a general hospital. *CLIN CHIM ACTA* 2020 2020-10-01;509:60-6.
26. Wang F, Yu J, Zhou Y, et al. The Use of TB-Specific Antigen/Phytohemagglutinin Ratio for Diagnosis and Treatment Monitoring of Extrapulmonary Tuberculosis. *FRONT IMMUNOL* 2018 2018-01-20;9:1047.

Tables

Due to technical limitations, table 1, 2 and 3 is only available as a download in the Supplemental Files section.

Figures

Figure 3

ESAT-6 ,CFP-10 ,PHA and TBAG/PHA ratio results in immunocompromised and immunocompetent ATB patients.

Figure 4

ESAT-6 ,CFP-10 ,PHA and TBAg/PHA ratio results and the activity of disease.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Table1.xls](#)
- [Table2.xls](#)
- [Table3.xlsx](#)